ImmunoScape presents at the 24th BioEquity Europe 2024

If you are headed to BioCentury Inc.‘s BioEquity Europe Conference and are interested in learning how ImmunoScape is working toward the development of TCR-based therapies against solid tumors, send us a message. Our Co-founder and VP of Innovation Michael Fehlings will be on the ground and will be setting up meetings.